26Sep 2021
Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives

Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives

Given the escalating global epidemic of obesity, advances in understanding this critical node will offer new precision medicine‐based therapeutic interventions and more appropriate dosing schedule for treating patients affected by obesity and with breast tumors resistant to endocrine therapies. However, an emerging but overlooked issue of clinical significance is the limited efficacy of the conventional endocrine therapies with selective estrogen receptor modulators (SERMs) or degraders (SERDs) and aromatase inhibitors (AIs) in patients affected by breast cancer and obesity. The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide.

  • #endo-diabetology

Like

Save

Share